PT - JOURNAL ARTICLE AU - Wan, Shanshan AU - Qu, Gaojing AU - Yu, Hui AU - Zhu, Haoming AU - Huang, Guoxin AU - Chen, Lei AU - Zhang, Meiling AU - Liu, Jiangtao AU - Pei, Bin TI - Features of creatine-kinase in COVID-19 patients within various specific periods: A cohort study AID - 10.1101/2020.10.28.20221119 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.28.20221119 4099 - http://medrxiv.org/content/early/2020/11/01/2020.10.28.20221119.short 4100 - http://medrxiv.org/content/early/2020/11/01/2020.10.28.20221119.full AB - Background Coronavirus disease 2019 (COVID-19) has been declared as a threat to the global. Due to the lack of efficient treatments, indicators were urgently needed during the evolvement of disease to analyze the illness and prognosis, and prevent the aggravation of COVID-19.Methods Patients’ general information, clinical type, all CK values and outcome were collected. CK value of all cases during disease course started from different initial time were analyzed.Results All cases underwent 504 tests of CK since symptom onset and the median value was 51.7 (35.0-91.5) U/L. The first median value on the day 8 from exposure onset was 78.1 (69.1-85.8) U/L then showed an upward trend from the day 8 to the day 12 (reaching a peak of 279.3 U/L), finally showed a fluctuation decline after the day 12. The CK median value in critical cases reached the peak (625.5 U/L) on the transforming date, and then decreased rapidly to the normal range. Before death, the CK median value in dead cases firstly increased until the day −14 with a peak as 470.0 U/L, then decreased with fluctuation until day −2, and finally increased again on the day 0.Conclusions CK reached its peak on the day when it became critical type, dynamic detection of CK can guide clinical judgment of prognosis. The increase of CK is a high risk factor of death. Severe cell damage 2 weeks before death might determines the outcome of the disease even if CK drops to the normal range afterward.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000031088Funding StatementNo external funding was received in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was unanimously approved by Ethics Committee of Xiangyang NO.1 people's hospital on February 12, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnyone who wishes to obtain the original data of this study with reasonable purposes can contact the correspondent author via email.